Eleni Patrikiou

Eleni Patrikiou

Auto-generated profile, based on publicly available information

Eleni Patrikiou

Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
STSotirios G. Tsiogkas
Sotirios G. Tsiogkas
ΑMΑthanasios Mavropoulos
Αthanasios Mavropoulos
DSDimitrios N. Skyvalidas
Dimitrios N. Skyvalidas
EPEleni Patrikiou
Eleni Patrikiou
NNNiki Ntavari
Niki Ntavari
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios

28 February 2025 in Rheumatology International
Verified
Journal Article
Open access
PDF file
EPELENI PARDALI
ELENI PARDALI
KKKaterina Maria Kontouli
Katerina Maria Kontouli
AGArriana Gkouvi
Arriana Gkouvi
ITIrene A. Tsakmaki
Irene A. Tsakmaki
EPEleni Patrikiou
Eleni Patrikiou
MGMaria G Grammatikopoulou
Maria G Grammatikopoulou
Sarcopenia is characterized by loss of muscle mass and reduced muscle function, presenting various adverse events, especially when inflammation is present. The present study aimed to determine the prevalence of sarcopenia and sarcopenic obesity among patients with rheumatic and musculoskeletal diseases (RMDs) and identify the risk for sarcopenia using two screening tools the Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) and the Mini Sarcopenia Risk Assessment (MSRA). In this single-center cross-sectional study, 220 consecutive patients visiting the Department of Rheumatology and Clinical Immunology at the University General Hospital of Larissa were interviewed. The EWGSOP criteria were used for the diagnosis of sarcopenia, while sensitivity, specificity, positive predictive values, number needed to screen, and positive and negative likelihood ratios were used to validate the diagnostic validity of the SARC-F and the MSRA. Univariate and multivariate logistic regression analyses were also applied to model the relationship between sarcopenia and other variables. In the total sample, 15.9% of patients were diagnosed with sarcopenia and one patient with sarcopenic obesity. The SARC-F (sensitivity 22.2%, specificity 75.6%), the 5-item (sensitivity 88.9%, specificity 18.9%), and the 7-item MSRA (sensitivity 91.7%, specificity 9.2%) presented poor clinical performance when used for screening alone. Univariate logistic regression analyses showed that underweight status, systemic sclerosis and appetite loss are strong contributors to sarcopenia diagnosis. Sarcopenia is prevalent among RMDs, and screening is essential within RMD clinics. None of the screening tools (SARC-F and MSRA) can stand alone in assessing sarcopenia in patients with RMDs. More research is required to understand sarcopenia in RMDs and validate the wide-using screening tools.

Verified
Journal Article
Open access
PDF file
SKStefania Kalampokini
Stefania Kalampokini
DGDespoina Georgouli
Despoina Georgouli
EPEleni Patrikiou
Eleni Patrikiou
APAntonios Provatas
Antonios Provatas
Varvara ValotassiouVarvara Valotassiou
Varvara Valotassiou
GXGeorgia Xiromerisiou
Georgia Xiromerisiou
Mutations in the gene encoding amyloid precursor protein (APP) cause autosomal dominant inherited Alzheimer’s disease (AD). We present a case of a 68-year-old female who presented with epileptic seizures, neuropsychiatric symptoms and progressive memory decline and was found to carry a novel APP variant, c.2062T>G pLeu688Val. A comprehensive literature review of all reported cases of AD due to APP mutations was performed in PubMed and Web of Science databases. We reviewed 98 studies with a total of 385 cases. The mean age of disease onset was 51.3 ± 8.3 (31–80 years). Mutations were most often located in exons 17 (80.8%) and 16 (12.2%). The most common symptoms were dementia, visuospatial symptoms, aphasia, epilepsy and psychiatric symptoms. Mutations in the β-amyloid region, and specifically exon 17, were associated with high pathogenicity and a younger age of disease onset. We describe the second reported APP mutation in the Greek population. APP mutations may act variably on disease expression and their phenotype is heterogeneous.

3 March 2026 in Maturitas
Verified
Journal Article
Open access
AGArriana Gkouvi
Arriana Gkouvi
KKKaterina Maria Kontouli
Katerina Maria Kontouli
EPELENI PARDALI
ELENI PARDALI
EPEleni Patrikiou
Eleni Patrikiou
ILIrene Lambrinoudaki
Irene Lambrinoudaki
MGMaria G Grammatikopoulou
Maria G Grammatikopoulou
Fibromyalgia and menopause often share common symptomatology, including musculoskeletal pain, fatigue, brain fog and sleep disturbances. The menopausal transition can represent a critical time at which fibromyalgia symptoms often worsen. This study examined the relationship between fibromyalgia and menopause using validated instruments. The Revised Fibromyalgia Impact Questionnaire (FIQR) was administered to 169 patients with fibromyalgia, and sociodemographic data and data on medication use were collected. Menopausal status was recorded, and the Greene Climacteric Scale (GCS) was administered. Linear regression analyses were performed to identify the predictors of more severe fibromyalgia impact and worse climacteric symptoms. Participants' mean age was 49.3 ± 9.6 years. Treatments for fibromyalgia included antidepressants (42.0% daily use), paracetamol, nonsteroidal anti-inflammatory drugs, and dietary supplements. Among the peri-/post-menopausal women, 6.25% were on hormone replacement therapy (HRT). The FIQR score was a significant predictor of the severity of menopausal symptoms (β = 0.38, 95% CI 0.26-0.51, p < 0.001), indicating that individuals with worse fibromyalgia tended to experience aggravated menopause symptomatology. Additionally, higher body mass index (BMI) was significantly associated with greater GCS scores (β = 0.84, 95% CI 0.35-1.33, p = 0.001) and more severe fibromyalgia impact (β = 1.1, 95% CI 0.61-1.57, p < 0.001, R2 = 0.11). Fibromyalgia preceded menopause in 51.0% of the sample and occurred concurrently in 21.9% of the sample. The findings suggest that fibromyalgia and menopausal symptoms overlap, worsening the symptom burden for patients in menopause. Higher FIQR scores were observed among patients with a greater BMI, indicating a greater overall disease impact and poorer quality of life.

11 August 2026 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
VSVasiliki Syrmou
Vasiliki Syrmou
TSTheodora Simopoulou
Theodora Simopoulou
EPEleni Patrikiou
Eleni Patrikiou
CLChristos Liaskos
Christos Liaskos
IAIoannis Alexiou
Ioannis Alexiou
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios
Background: Malignancy identified around the onset of idiopathic inflammatory myopathy (IIM) is referred to as cancer-associated myositis (CAM), but population-specific data remain relatively limited. Aim: To describe the prevalence, clinical features, and risk factors for CAM over a 20-year period in a single tertiary centre in Greece. Methods: A retrospective analysis was conducted on 113 IIM cases treated between 2001 and 2024 in our department, which is a referral centre for rheumatic disease in Central Greece. Medical records were evaluated for demographics, clinical characteristics, autoantibody profile, and comorbidities. CAM was defined as cases of myositis complicated by the onset or recurrence of cancer within 3 years before or after the diagnosis of myositis. Results: CAM was identified in 25 (22.1%) patients. Older age and dermatomyositis subtype were associated with CAM. Anti-TIF1γ autoantibody confers significantly higher risk (OR 6.9, p < 0.001), while anti-Jo1 lowers risk (OR 0.13, p = 0.022). Gottron’s papules and Holster sign were significantly associated with CAM. Raynaud’s phenomenon, interstitial lung disease and the non-interstitial pneumonia pattern appeared protective. Hypothyroidism was less common, while myocardial infarction was more frequent in CAM. Breast, ovarian, and lung cancers were the most common malignancies identified. In most cases, malignancy was asymptomatic (85%) and was determined upon screening. Survival was significantly lower in CAM p < 0.001 with the survival rate dropping down to 45% at 31 months vs 95.9% in non-CAM. Median survival was 21 months in CAM cases (1–79 months). Conclusion: CAM accounts for a substantial proportion of IIM cases. Anti-TIF1γ positivity, older age, absence of Raynaud’s phenomenon, and absence of ILD may serve as clinical flags in our cohort. Comprehensive cancer screening, including GI endoscopy, remains vital in the initial assessment and follow-up, primarily upon relapses and lack of remission. Key Points • Population-based studies on cancer-associated myopathy have established a clear, strong link between idiopathic inflammatory myopathies (IIM) and malignancy, often termed cancer-associated myositis (CAM) .• This study examines CAM prevalence, features, and risk factors over 20 years at a Greek tertiary center .• CAM was present in 22% of IIM patients, mostly asymptomatic (85%), identified through screening; breast, ovarian, and lung cancers were the common malignancies .• Akin to previous studies, anti-TIF1γ autoantibody confers a significantly higher risk, while anti-Jo1 lowers risk .

27 February 2026 in Rheumatology
Verified
Journal Article
Open access
PDF file
AGArriana Gkouvi
Arriana Gkouvi
EPEleni Patrikiou
Eleni Patrikiou
MGMaria G Grammatikopoulou
Maria G Grammatikopoulou
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios